Molecular structures and functional relationships in clostridial neurotoxins

FEBS Journal

Volumn 278, Issue 23, 2011, Pages 4467-4485

  Swaminathan, Subramanyam ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

botulinum neurotoxin; botulism; catalytic activity; drug discovery; neuroexocytosis; structure function; substrate enzyme complex; tetanus; translocation; X ray crystallography; zinc endopeptidase

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; TETANUS TOXIN; TRIPEPTIDE; ZINC;

AMINO TERMINAL SEQUENCE; BINDING SITE; BIOCATALYSIS; BOTULISM; CHIMERA; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN TRANSPORT; REVIEW; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; TOXIN ANALYSIS; TOXIN STRUCTURE;

BINDING SITES; BOTULINUM TOXINS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PROTEIN CONFORMATION; SNARE PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TETANUS TOXIN;

ANIMALIA; CLOSTRIDIUM BOTULINUM;

EID: 81555214403     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08183.x     Document Type: Review

References (108)

1. Schiavo G, Matteoli M, &, Montecucco C, (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80, 717-766. (Pubitemid 30164948)
2. Gill DM, (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46, 86-94. (Pubitemid 12101491)
3. Montecucco C, &, Schiavo G, (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13, 1-9.
4. Schiavo G, Rossetto O, Benfenati F, Poulain B, &, Montecucco C, (1994) Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann NY Acad Sci 710, 65-75. (Pubitemid 24119183)
5. Montecucco C, &, Schiavo G, (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28, 423-472. (Pubitemid 26015975)
6. Sobel JD, (2005) Botulism. Clin Infect Dis 41, 1167-1173.
7. Oguma K, Fujinaga Y, &, Inoue K, (1995) Structure and function of Clostridium botulinum toxins. Microbiol Immunol 39, 161-168.
8. Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, &, Barbieri JT, (2010) Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49, 8117-8126.
9. Montecucco C, Papini E, &, Schiavo G, (1994) Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett 346, 92-98. (Pubitemid 24183835)
10. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, &, Swaminathan S, (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386, 233-245.
11. Lacy DB, Tepp W, Cohen AC, DasGupta BR, &, Stevens RC, (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5, 898-902. (Pubitemid 28467413)
12. Swaminathan S, &, Eswaramoorthy S, (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7, 693-699. (Pubitemid 30636683)
13. Lacy DB, &, Stevens RC, (1999) Sequence homology and structural analysis of clostridial neurotoxins. J Mol Biol 291, 1091-1104. (Pubitemid 29423772)
14. c of tetanus neurotoxin. Nat Struct Biol 4, 788-792.
15. Murzin AG, Lesk AM, &, Chothia C, (1992) beta-Trefoil fold. Patterns of structure and sequence in the Kunitz inhibitors interleukins-1beta and 1alpha and fibroblast growth factors. J Mol Biol 223, 531-543.
16. Simpson LL, (1984) The binding fragment from tetanus toxin antagonizes the neuromuscular blocking actions of botulinum toxin. J Pharmacol Exp Ther 229, 182-187. (Pubitemid 14082929)
17. Simpson LL, (1984) Botulinum toxin and tetanus toxin recognize similar membrane determinants. Brain Res 205, 177-180. (Pubitemid 14117861)
18. Bigalke H, Muller H, &, Dreyer F, (1986) Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. Toxicon 24, 1065-1074. (Pubitemid 17215075)
19. Marxen P, &, Bigalke H, (1989) Tetanus toxin: inhibitory action in chromaffin cells is initiated by specified types of gangliosides and promoted in low ionic strength solution. Neurosci Lett 107, 261-266.
20. Marxen P, Fuhrmann U, &, Bigalke H, (1989) Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon 27, 849-859. (Pubitemid 19210674)
21. Binz T, &, Rummel A, (2009) Cell entry strategy of clostridial neurotoxins. J Neurochem 109, 1584-1595.
22. Kitamura M, Takamiya K, Aizawa S, Furukawa K, &, Furukawa K, (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim Biophys Acta 1441, 1-3. (Pubitemid 29469431)
23. Montecucco C, (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11, 314-317.
24. Muraro L, Tosatto S, Motterlini L, Rossetto O, &, Montecucco C, (2009) The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun 380, 76-80.
25. Halpern JL, &, Loftus A, (1993) Characterization of the receptor-binding domain of tetanus toxin. J Biol Chem 268, 11188-11192. (Pubitemid 23162310)
26. Shapiro RS, Specht CD, Collins BE, Woods AS, Cotter RJ, &, Schnaar RL, (1997) Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand. J Biol Chem 272, 30380-30386. (Pubitemid 27512247)
27. Kamata Y, Yoshimoto M, &, Kozaki S, (1997) Interaction between botulinum neurotoxin type A and ganglioside: ganglioside inactivates the neurotoxin and quenches its tryptophan fluorescence. Toxicon 35, 1337-1340. (Pubitemid 27326956)
28. Emsley P, Fotinou C, Black I, Fairweather NF, Charles IG, Watts C, Hewitt E, &, Isaacs NW, (2000) The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 275, 8889-8894. (Pubitemid 30180245)
29. Fotinou C, Emsley P, Black I, Ando H, Ishida H, Kiso M, Sinha KA, Fairweather NF, &, Isaacs NW, (2001) The crystal structure of tetanus toxin Hc fragment complexed with a synthetic Gt1b analogue suggests cross-linking between ganglioside receptors and the toxin. J Biol Chem 276, 32274-32281.
30. Rummel A, Bade S, Alves J, Bigalke H, &, Binz T, (2003) Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J Mol Biol 326, 835-847. (Pubitemid 36279323)
31. Rummel A, Mahrhold S, Bigalke H, &, Binz T, (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51, 631-644.
32. Jayaraman S, Eswaramoorthy S, Kumaran D, &, Swaminathan S, (2005) Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin. Proteins 61, 288-295. (Pubitemid 41429136)
33. Stenmark P, Dupuy J, Imamura A, Kiso M, &, Stevens RC, (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4, e1000129.
34. Fu Z, Chen C, Barbieri JT, Kim JJ, &, Baldwin MR, (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641.
35. Schmitt J, Karalewitz AP, Benefield DA, Mushrush DJ, Pruitt RN, Spiller BW, Barbieri JT, &, Lacy DB, (2010) Structural analysis of botulinum neurotoxin type G receptor binding. Biochem Cell Biol 49, 5200-5205.
36. Stenmark P, Dong M, Dupuy J, Chapman ER, &, Stevens RC, (2010) Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J Mol Biol 397, 1287-1297.
37. Strotmeier J, Lee K, Volker AK, Mahrhold S, Zong Y, Zeiser J, Zhou J, Pich A, Bigalke H, Binz T, et al. (2010) Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem J 431, 207-216.
38. Tsukamoto K, Kozai Y, Ihara H, Kohda T, Mukamoto M, Tsuji T, &, Kozaki S, (2008) Identification of the receptor-binding sites in the carboxyl-terminal half of the heavy chain of botulinum neurotoxin types C and D. Microb Pathog 44, 484-493.
39. Lazarovici P, &, Yavin E, (1986) Affinity-purified tetanus neurotoxin interaction with synaptic membranes: properties of a protease-sensitive receptor component. Biochem Cell Biol 25, 7047-7054. (Pubitemid 17201611)
40. Pierce EJ, Davison MD, Parton RG, Habig WJ, &, Cruitchley DR, (1986) Characterization of tetanus toxin binding to rat brain membranes. Evidence for a high-affinity proteinase-sensitive receptor. Biochem J 236, 845-852. (Pubitemid 16067128)
41. Evans DM, Williams RS, Shone CC, Hambleton P, Melling J, &, Dolly JO, (1986) Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. Eur J Biochem 154, 409-416.
42. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, &, Chapman ER, (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596.
43. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, &, Chapman ER, (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162, 1293-1303. (Pubitemid 37210885)
44. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, et al. (2007) Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci USA 104, 359-364. (Pubitemid 46068036)
45. Dong M, Tepp WH, Liu H, Johnson EA, &, Chapman ER, (2007) Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol 179, 1511-1522.
46. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, &, Chapman ER, (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19, 5226-5237.
47. Yeh FL, Dong M, Yao J, Tepp WH, Lin G, Johnson EA, &, Chapman ER, (2010) SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog 6, e1001207.
48. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapmann ER, &, Stevens RC, (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (Lond) 444, 1019-1020.
49. Jin R, Rummel A, Binz T, &, Brunger AT, (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature (Lond) 444, 1092-1095. (Pubitemid 46018531)
50. Eswaramoorthy S, Kumaran D, Keller J, &, Swaminathan S, (2004) Role of metals in the biological activity of Clostridium botulinum neurotoxins. Biochemistry 43, 2209-2216. (Pubitemid 38279966)
51. Koriazova L, &, Montal M, (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10, 13-18. (Pubitemid 36034171)
52. Fischer A, &, Montal M, (2007) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282, 29604-29611. (Pubitemid 350043363)
53. Fischer A, Mushrush DJ, Lacy DB, &, Montal M, (2008) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4, e1000245.
54. Masuyer G, Thiyagarajan N, James PL, Marks PHH, Chaddock J, &, Acharya KR, (2009) Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. Biochem Biophys Res Commun 381, 50-53.
55. Montal M, (2009) Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon 54, 565-569.
56. Galloux M, Vitrac H, Montagner C, Raffestin S, Popoff MR, Chenal A, Forge V, &, Gillet D, (2008) Membrane interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. J Biol Chem 283, 27668-27676.
57. Agarwal R, Schmidt JJ, Stafford RG, &, Swaminathan S, (2009) Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol 16, 789-794.
58. Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, &, Montal M, (2007) Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 3, 1191-1194. (Pubitemid 47510272)
59. Schmid MF, Robinson JP, &, DasGupta BR, (1993) Direct visualization of botulinum neurotoxin induced channels in phospholipid vesicles. Nature 364, 827-830. (Pubitemid 23261767)
60. Matthews BW, (1988) Structural basis of the action of thermolysin and related zinc peptides. Acc Chem Res 21, 333-340.
61. Agarwal R, Eswaramoorthy S, Kumaran D, Binz T, &, Swaminathan S, (2004) Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212→Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 43, 6637-6644. (Pubitemid 38697563)
62. Agarwal R, Binz T, &, Swaminathan S, (2005) Analysis of active site residues of botulinum neurotoxin E by mutational, functional and structural studies: Glu335Gln is an apoenzyme. Biochemistry 44, 8291-8302. (Pubitemid 40799910)
63. Agarwal R, Binz T, &, Swaminathan S, (2005) Structural analysis of botulinum neurotoxin serotype f light chain: implications on substrate binding and inhibitor design. Biochemistry 44, 11758-11765. (Pubitemid 41262710)
64. Arndt JW, Chai Q, Christian T, &, Stevens RC, (2006) Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity. Biochem Cell Biol 45, 3255-3262. (Pubitemid 43376344)
65. Arndt JW, Yu W, Bi F, &, Stevens RC, (2005) Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry 44, 9574-9580. (Pubitemid 40994351)
66. Jin R, Sikorra S, Stegmann CM, Pich A, Binz T, &, Brunger AT, (2007) Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry 46, 10685-10693. (Pubitemid 47417260)
67. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, &, Swaminathan S, (2008) Structure and substrate based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem 283, 18883-18891.
68. Segelke B, Knapp M, Kadkhodayan S, Balhorn R, &, Rupp B, (2004) Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity. Proc Natl Acad Sci USA 101, 6888-6893. (Pubitemid 38596413)
69. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, Janda KD, &, Allen KN, (2007) Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol 14, 533-542. (Pubitemid 46765150)
70. Rao KN, Kumaran D, Binz T, &, Swaminathan S, (2005) Structural studies on the catalytic domain of clostridial tetanus toxin. Toxicon 45, 929-939. (Pubitemid 40719795)
71. Breidenbach MA, &, Brunger AT, (2005) 2.3 Å crystal structure of tetanus neurotoxin light chain. Biochemistry 44, 7450-7457. (Pubitemid 40695998)
72. 365 of the botulinum neurotoxin type A light chain are involved in transition state stabilization. Biochemistry 41, 1717-1723. (Pubitemid 34132245)
73. Li L, Binz T, Niemann H, &, Singh BR, (2000) Probing the mechanistic role of glutamate residues in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 39, 2399-2405. (Pubitemid 30130092)
74. Li Y, Foran P, Fairweather NF, Paiva AD, Weller U, Dougan G, &, Dolly JO, (1994) A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Biochemistry 33, 7014-7020. (Pubitemid 24190828)
75. 2O of zinc enzymes. Proc Natl Acad Sci USA 87, 220-224.
76. Vallee BL, &, Auld DS, (1990) Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry 29, 5647-5659. (Pubitemid 20192431)
77. Fu F, Lomneth RB, Cai S, &, Singh BR, (1998) Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 37, 5267-5278. (Pubitemid 28176528)
78. Silvaggi NR, Wilson D, Tzipori S, &, Allen KN, (2008) Catalytic features of the botulinum neurotoxin a light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 47, 5736-5745. (Pubitemid 351747052)
79. Simpson LL, Maksymowych AB, &, Hao S, (2001) The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276, 27034-27041.
80. Agarwal R, &, Swaminathan S, (2008) SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E. J Biol Chem 283, 25944-25951.
81. Breidenbach MA, &, Brunger A, (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929. (Pubitemid 40037157)
82. Kumaran D, Rawat R, Ahmed SA, &, Swaminathan S, (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog 4, e1000165.
83. Swaminathan S, Eswaramoorthy S, &, Kumaran D, (2004) Structure and enzymatic activity of botulinum neurotoxins. Mov Disord 19 (Suppl. 8), S17-S22. (Pubitemid 38967507)
84. Sikorra S, Henke T, Galli T, &, Binz T, (2008) Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins. J Biol Chem 283, 21145-21152.
85. Schmidt JJ, &, Stafford RG, (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 44, 4067-4073. (Pubitemid 40358059)
86. Marks JD, (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 19 (Suppl. 8), S101-S108. (Pubitemid 38967518)
87. Lightstone FC, Prieto MC, Singh AK, Piqueras MC, Whittal RM, Knapp MS, Balhorn R, &, Roe DC, (2000) Identification of novel small molecule ligands that bind to tetanus toxin. Chem Res Toxicol 13, 356-362. (Pubitemid 30327155)
88. Eswaramoorthy S, Kumaran D, &, Swaminathan S, (2001) Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B. Acta Crystallogr D 57, 1743-1746. (Pubitemid 33037762)
89. Zou J, Miao WY, Ding FH, Meng JY, Ye HJ, Jia GR, He XY, Sun GZ, &, Li PZ, (1985) The effect of toosendanin on monkey botulism. J Tradit Chin Med 5, 29-30.
90. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, Dickerson TJ, Johnson EA, Janda KD, &, Montal M, (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 106, 1330-1335.
91. Burnett JC, Henchal EA, Schmaljohn AL, &, Bavari S, (2005) The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 4, 281-297. (Pubitemid 41135787)
92. Burnett JC, Opsenica D, Sriraghavan K, Panchal RG, Ruthel G, Hermone AR, Nguyen TL, Kenny TA, Lane DJ, McGrath CF, et al. (2007) A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J Med Chem 50, 2127-2136. (Pubitemid 46683065)
93. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, Stafford RG, Lane DJ, Kenny TA, McGrath CF, et al. (2007) Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 282, 5004-5014. (Pubitemid 47100957)
94. Burnett JC, Schmidt JJ, McGrath CF, Nguyen TL, Hermone AR, Panchal RG, Vennerstrom JL, Kodukula K, Zaharevitz DW, Gussio R, et al. (2005) Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg Med Chem 13, 333-341. (Pubitemid 39642917)
95. Burnett JC, Schmidt JJ, Stafford RG, Panchal RG, Nguyen TL, Hermone AR, Vennerstrom JL, McGrath CF, Lane DJ, Sausville EA, et al. (2003) Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun 310, 84-93. (Pubitemid 37162766)
96. Pang YP, Vummenthala A, Mishra RK, Park JG, Wang S, Davis J, Millard CB, &, Schmidt JJ, (2010) Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS ONE 4, e7730.
97. Tang J, Park JG, Millard CB, Schmidt JJ, &, Pang YP, (2007) Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS ONE 2, e761.
98. Lai H, Feng M, Roxas-Duncan V, Dakshinamurthy S, Smith LA, &, Yang DC, (2009) Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. Arch Biochem Biophys 491, 75-84.
99. Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, Lai H, Gul N, Yang DC, &, Smith LA, (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother 53, 3478-3486.
100. Capkova K, Salzameda NT, &, Janda KD, (2009) Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins. Toxicon 54, 575-582.
101. Zuniga JE, Hammill JT, Drory O, Nuss JE, Burnett JC, Gussio R, Wipf P, Bavari S, &, Brunger AT, (2010) Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A. PLoS ONE 5, e11378.
102. Zuniga JE, Schmidt JJ, Fenn T, Burnett JC, Arac D, Gussio R, Stafford RG, Badie SS, Bavari S, &, Brunger AT, (2008) A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure (Camb) 16, 1588-1597.
103. Hale M, Oyler G, Swaminathan S, &, Ahmed SA, (2010) Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J Biol Chem 286, 1802-1811.
104. Schmidt JJ, &, Stafford RG, (2002) A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett 532, 423-426. (Pubitemid 35441386)
105. Foster KA, (2009) Engineered toxins: new therapeutics. Toxicon 54, 587-592.
106. Chen S, &, Barbieri JT, (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci 106, 9180-9184.
107. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, &, Montal M, (2008) Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem 283, 3997-4003.
108. Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A, Bodeker MO, Gilmore MA, Fernandez-Salas E, Francis J, Steward LE, et al. (2008) Novel chimeras of botulinum neurotoxin/A and/E unveil contributions from the binding, translocation and protease domains to their functional characteristics. J Biol Chem 283, 16993-17002.